Filing Flows › Comparisons › AKTS vs CVSI
Aktis Oncology vs CV Sciences: AKTS and CVSI compared
Aktis Oncology is the larger company: $3.4M of revenue in its latest quarter (Q2 2026) against $3.0M for CV Sciences (Q2 2026). Aktis Oncology is growing faster (+111% against -18% a year earlier). CV Sciences is more profitable, with an operating margin of -10.1% against -854.0%.
Where the money goes: AKTS and CVSI
Aktis Oncology (AKTS) · Q2 2026
Aktis Oncology, Q2 2026: revenue $3.4M (+111% year over year), operating margin -854.0%, net loss $24.1M, operating cash flow −$20.6M. The chart follows the revenue to costs, profit and cash.
CV Sciences (CVSI) · Q2 2026
CV Sciences, Q2 2026: revenue $3.0M (-18% year over year), operating margin -10.1%, net loss $775K, operating cash flow $20K. The chart follows the revenue to costs, profit and cash.
| Aktis Oncology (AKTS) | CV Sciences (CVSI) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $3.4M | $3.0M |
| Revenue growth, Y/Y | +111% | -18% |
| Operating margin | -854.0% | -10.1% |
| Net earnings | −$24.1M | −$775K |
| Net margin | -713.5% | -26.0% |
| Operating cash flow | −$20.6M | $20K |
| Free cash flow | — | $13K |
Questions
Which is bigger, Aktis Oncology or CV Sciences?
Aktis Oncology is the larger company: $3.4M of revenue in its latest quarter (Q2 2026) against $3.0M for CV Sciences (Q2 2026).
Is Aktis Oncology or CV Sciences growing faster?
Aktis Oncology is growing faster (+111% against -18% a year earlier).
Which is more profitable, Aktis Oncology or CV Sciences?
CV Sciences is more profitable, with an operating margin of -10.1% against -854.0%.
More: Aktis Oncology earnings · how Aktis Oncology makes money · CV Sciences earnings · how CV Sciences makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 13, 2026; 10-Q filed Aug 13, 2026). Fiscal quarters can end on different dates. Not investment advice.